Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
暂无分享,去创建一个
L Biganzoli | F Puglisi | M Buyse | M. Buyse | C. Criscitiello | G. Curigliano | F. Puglisi | L. Boni | G. Arpino | A. Leo | A. Minisini | M. Pestrin | A. Di Leo | L. Biganzoli | C. Tondini | S. Cinieri | G. Sanna | A M Minisini | A Di Leo | E Risi | L. Malorni | A. Bernardo | I. Migliaccio | A. McCartney | G Curigliano | C. Biagioni | E. Risi | E. Moretti | S Cinieri | L Malorni | C A Tondini | K D’Hollander | G Arpino | A Bernardo | A Martignetti | C Criscitiello | M Pestrin | G Sanna | E Moretti | C Biagioni | A McCartney | L Boni | I Migliaccio | K. d'Hollander | A. Martignetti
[1] D. Heitjan,et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.
[2] M. Goetz,et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Mills,et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.
[4] J. Lewis-Wambi,et al. Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA , 2015, Breast Cancer Research.
[5] S. Loi,et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.
[6] R. Clarke,et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.
[7] Rachel Schiff,et al. Mechanisms of endocrine resistance in breast cancer. , 2011, Annual review of medicine.
[8] E. Winer,et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.
[9] C. Hudis,et al. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer , 2017, Clinical Cancer Research.
[10] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[11] S. Loi,et al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). , 2016, The oncologist.
[12] P. Neven,et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] K. Gelmon,et al. Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.
[14] M. Ellis,et al. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer , 2015, Clinical Cancer Research.
[15] P F Thall,et al. New designs for the selection of treatments to be tested in randomized clinical trials. , 1994, Statistics in medicine.